Description
In this episode, we dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining us are leading experts in oncology Zarnie Lwin, Susan Harden and Wei-Sen Lam.
Together, they explore the significance of the ADRIATIC trial results, debate the role of prophylactic cranial irradiation (PCI) in the treatment of SCLC, and provide insights into ongoing studies that may further improve outcomes for patients. Tune in for a deep dive into the latest research and expert perspectives on this aggressive cancer.
Podcasters:
Associate Professor Zarnie Lwin, OAM, Medical Oncologist at Royal Brisbane Women’s Hospital and the University of Queensland, QLD
Associate Professor Susan Harden, Radiation Oncologist at Peter MacCallum Cancer Centre and Monash Cancer Registries, VIC
Dr. Wei-Sen Lam, Medical Oncologist and TeleHealth lead at Fiona Stanley and Esperance Hospitals, WA
In this TOGA podcast, we provide an overview of the treatment options for rare subtypes of oncogene driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2,3 and other rare mutations in NSCLC. The importance of testing all patients is discussed as...
Published 08/30/24
In this TOGA podcast, we provide an overview of the recent neoadjuvant, adjuvant, and perioperative IO data, the options and considerations for treatment and the current reimbursement landscape. Dr Pei Ni Ding, Medical Oncologist from Westmead and Nepean Hospitals Sydney, is joined by Dr Samantha...
Published 07/25/24